Showing results (521-530 of 763) with videos related to
Sort By:
Pageof 77
JCI Insight|September 20, 2019
Alteration of thyroid hormone signaling triggers the diabetes-induced pathological growth, remodeling, and dedifferentiation of podocytesValentina Benedetti, Angelo Michele Lavecchia, Monica Locatelli, et al.The Lancet. Diabetes & Endocrinology|March 14, 2014
Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trialAneliya Parvanova, Irene M van der Meer, Ilian Iliev, et al.Journal of the American Society of Nephrology : JASN|December 8, 2004
Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial resultsGiuseppe Remuzzi, Piero Ruggenenti, Annalisa Perna, et al.Iscience|September 27, 2023
Thyroid hormone treatment counteracts cellular phenotypical remodeling in diabetic organsAngelo M Lavecchia, Polyxeni Mantzouratou, Domenico Cerullo, et al.Lancet (London, England)|November 9, 2010
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trialDick de Zeeuw, Rajiv Agarwal, Michael Amdahl, et al.Journal of the American Society of Nephrology : JASN|May 28, 2009
ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcomeDario Cattaneo, Piero Ruggenenti, Sara Baldelli, et al.The American Journal of Pathology|May 28, 2013
Angiotensin II contributes to diabetic renal dysfunction in rodents and humans via Notch1/Snail pathwayElena Gagliardini, Norberto Perico, Paola Rizzo, et al.Diabetologia|April 2, 2017
MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathyCristina Zanchi, Daniela Macconi, Piera Trionfini, et al.Journal of the American Society of Nephrology : JASN|February 3, 2023
Intensive BP Control in Patients with CKD and Risk for Adverse OutcomesElaine Ku, Charles E McCulloch, Lesley A Inker, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 27, 2023
Anti-Phospholipase A2 Receptor 1 and Anti-Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort StudyPiero Ruggenenti, Linda Reinhard, Barbara Ruggiero, et al.Pageof 77